NVS

Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Players: Pfizer, Novartis, Bayer, Astellas and Sarepta. Profile: next-gen AAV delivery, including engineered capsids, targeting, safety and scalable manufacturing.Dublin, Oct.

Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.

Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.

Novartis just dropped its Q3 2026 numbers and the headline is simple. Earnings power looks squeezed while the share price into the release had been grinding higher, with a 30‑day gain of about 7.5% and a flat 90‑day track. That is a sentiment clash.

Novartis reported Q3 2026 sales of US$14.52b and net income of US$1.20b, and then raised its full year core operating income outlook after margin expansion and strong contributions from priority medicines.

Novartis (NYSE:NVS) reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and productivity initiatives, while raising its full-year outlook for core operating income.

Novartis stock rose slightly early Tuesday on strong third-quarter income, but the second biggest moneymaker fell short.

Priority brands offset generic erosion as margin expands and pipeline advances.

Novartis beats Q3 earnings estimates and raises its 2026 operating income outlook as Kisqali, Kesimpta and Scemblix offset generic competition.